ZYME
insider transactionsZymeworks Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-140.4K
0 buy · 140.4K sell
Net value · 365d
-$3.4M
$0 in · $3.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
9
0 buy · 140.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
EVP, General Counsel
$0
119.0K sh
Own New
-
Grant·A
EVP, General Counsel
$0
178.0K sh
Own New
-
Grant·A
EVP, Head of Research & Devel…
$0
76.0K sh
Own New
-
Grant·A
EVP, Head of Research & Devel…
$0
47.0K sh
Own New
-
Grant·A
EVP, Head of Research & Devel…
$0
70.0K sh
Own New
-
Grant·A
EVP, Chief Business Officer
$0
76.0K sh
Own New
-
Grant·A
EVP, Chief Business Officer
$0
47.0K sh
Own New
-
Grant·A
EVP, Chief Business Officer
$0
70.0K sh
Own New
-
Grant·A
Kristin Stafford KEY
EVP, Chief Financial Officer
$0
50.0K sh
Own New
-
Grant·A
Kristin Stafford KEY
EVP, Chief Financial Officer
$0
119.0K sh
Own New
-
Grant·A
Kristin Stafford KEY
EVP, Chief Financial Officer
$0
178.0K sh
Own New
-
Exercise·M
EVP & Chief Medical Officer
$0
17.7K sh
Own +100%
-
Sell·S
EVP & Chief Medical Officer
$211.1K
9.3K sh · $22.67
Own -26%
-
Exercise·M
EVP & Chief Medical Officer
$0
17.7K sh
Own +96%
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
66.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
47.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
70.0K sh
Own New
-
Exercise·M
Chief Scientific Officer
$0
17.7K sh
Own +100%
-
Sell·S
Chief Scientific Officer
$216.8K
9.6K sh · $22.67
Own -16%
-
Exercise·M
Chief Scientific Officer
$0
17.7K sh
Own +44%
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Chair & CEO
$0
222.0K sh
Own New
-
Grant·A
Chair & CEO
$0
144.0K sh
Own New
-
Grant·A
Chair & CEO
$0
216.0K sh
Own New
-
Exercise·M
Chair & CEO
$0
64.0K sh
Own +100%
-
Sell·S
Chair & CEO
$689.8K
30.4K sh · $22.67
Own -12%
-
Exercise·M
Chair & CEO
$0
64.0K sh
Own +33%
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
11.5K sh
Own New
-
Grant·A
EVP & Chief Operating Officer
$0
66.0K sh
Own New
-
Grant·A
EVP & Chief Operating Officer
$0
47.0K sh
Own New
-
Grant·A
EVP & Chief Operating Officer
$0
70.0K sh
Own New
-
Exercise·M
EVP & Chief Operating Officer
$0
17.7K sh
Own +100%
-
Sell·S
EVP & Chief Operating Officer
$138.8K
6.1K sh · $22.67
Own -4%
-
Exercise·M
EVP & Chief Operating Officer
$0
17.7K sh
Own +15%
-
Grant·A
Director
$0
15.4K sh
Own New
-
Grant·A
Director
$0
23.0K sh
Own New
-
Grant·A
EVP, Chief Bus & Fin Officer
$4.8K
459 sh · $10.55
Own New
-
Exercise·M
EVP & Chief Medical Officer
$0
20.0K sh
Own New
-
Sell·S
EVP & Chief Medical Officer
$264.5K
10.5K sh · $25.10
Own -36%
-
Exercise·M
EVP & Chief Medical Officer
$0
20.0K sh
Own +225%
-
Exercise·M
Chief Scientific Officer
$0
20.0K sh
Own New
-
Exercise·M
Chief Scientific Officer
$0
17.2K sh
Own New
-
Sell·S
Chief Scientific Officer
$271.6K
10.8K sh · $25.10
Own -21%
-
Exercise·M
Chief Scientific Officer
$0
20.0K sh
Own +64%
-
Sell·S
Chief Scientific Officer
$233.1K
9.3K sh · $25.10
Own -23%
-
Exercise·M
Chief Scientific Officer
$0
17.2K sh
Own +74%
-
Exercise·M
Chair & CEO
$0
66.7K sh
Own +3333300%
-
Exercise·M
Chair & CEO
$0
47.7K sh
Own New
-
Sell·S
Chair & CEO
$795.2K
31.7K sh · $25.10
Own -14%
-
Exercise·M
Chair & CEO
$0
66.7K sh
Own +42%
-
Sell·S
Chair & CEO
$568.6K
22.7K sh · $25.10
Own -13%
-
Exercise·M
Chair & CEO
$0
47.7K sh
Own +36%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 13, 2026 | Paul R Schneider | Grant A | 119.0K | $0 |
| May 13, 2026 | Paul R Schneider | Grant A | 178.0K | $0 |
| Apr 9, 2026 | Adam Schayowitz | Grant A | 76.0K | $0 |
| Apr 9, 2026 | Adam Schayowitz | Grant A | 47.0K | $0 |
| Apr 9, 2026 | Adam Schayowitz | Grant A | 70.0K | $0 |
| Apr 9, 2026 | Scott Platshon | Grant A | 76.0K | $0 |
| Apr 9, 2026 | Scott Platshon | Grant A | 47.0K | $0 |
| Apr 9, 2026 | Scott Platshon | Grant A | 70.0K | $0 |
| Apr 6, 2026 | Kristin Stafford KEY | Grant A | 50.0K | $0 |
| Apr 6, 2026 | Kristin Stafford KEY | Grant A | 119.0K | $0 |
| Apr 6, 2026 | Kristin Stafford KEY | Grant A | 178.0K | $0 |
| Jan 12, 2026 | Jeffrey T L Smith | Exercise M | 17.7K | $0 |
| Jan 12, 2026 | Jeffrey T L Smith | Sell S | 9.3K | $211.1K |
| Jan 12, 2026 | Jeffrey T L Smith | Exercise M | 17.7K | $0 |
| Jan 12, 2026 | Kelvin Neu | Grant A | 7.7K | $0 |
| Jan 12, 2026 | Kelvin Neu | Grant A | 11.5K | $0 |
| Jan 12, 2026 | Paul Andrew Moore | Grant A | 66.0K | $0 |
| Jan 12, 2026 | Paul Andrew Moore | Grant A | 47.0K | $0 |
| Jan 12, 2026 | Paul Andrew Moore | Grant A | 70.0K | $0 |
| Jan 12, 2026 | Paul Andrew Moore | Exercise M | 17.7K | $0 |
| Jan 12, 2026 | Paul Andrew Moore | Sell S | 9.6K | $216.8K |
| Jan 12, 2026 | Paul Andrew Moore | Exercise M | 17.7K | $0 |
| Jan 12, 2026 | Susan Mahony | Grant A | 7.7K | $0 |
| Jan 12, 2026 | Susan Mahony | Grant A | 11.5K | $0 |
| Jan 12, 2026 | Robert E Landry | Grant A | 7.7K | $0 |
| Jan 12, 2026 | Robert E Landry | Grant A | 11.5K | $0 |
| Jan 12, 2026 | Kenneth Galbraith KEY | Grant A | 222.0K | $0 |
| Jan 12, 2026 | Kenneth Galbraith KEY | Grant A | 144.0K | $0 |
| Jan 12, 2026 | Kenneth Galbraith KEY | Grant A | 216.0K | $0 |
| Jan 12, 2026 | Kenneth Galbraith KEY | Exercise M | 64.0K | $0 |
| Jan 12, 2026 | Kenneth Galbraith KEY | Sell S | 30.4K | $689.8K |
| Jan 12, 2026 | Kenneth Galbraith KEY | Exercise M | 64.0K | $0 |
| Jan 12, 2026 | Gregory Austin Ciongoli | Grant A | 7.7K | $0 |
| Jan 12, 2026 | Gregory Austin Ciongoli | Grant A | 11.5K | $0 |
| Jan 12, 2026 | Carlos Campoy | Grant A | 7.7K | $0 |
| Jan 12, 2026 | Carlos Campoy | Grant A | 11.5K | $0 |
| Jan 12, 2026 | Mark Hollywood | Grant A | 66.0K | $0 |
| Jan 12, 2026 | Mark Hollywood | Grant A | 47.0K | $0 |
| Jan 12, 2026 | Mark Hollywood | Grant A | 70.0K | $0 |
| Jan 12, 2026 | Mark Hollywood | Exercise M | 17.7K | $0 |
| Jan 12, 2026 | Mark Hollywood | Sell S | 6.1K | $138.8K |
| Jan 12, 2026 | Mark Hollywood | Exercise M | 17.7K | $0 |
| Jan 12, 2026 | Brian N Cherry | Grant A | 15.4K | $0 |
| Jan 12, 2026 | Brian N Cherry | Grant A | 23.0K | $0 |
| Jan 6, 2026 | Leone D Patterson | Grant A | 459 | $4.8K |
| Jan 5, 2026 | Jeffrey T L Smith | Exercise M | 20.0K | $0 |
| Jan 5, 2026 | Jeffrey T L Smith | Sell S | 10.5K | $264.5K |
| Jan 5, 2026 | Jeffrey T L Smith | Exercise M | 20.0K | $0 |
| Jan 5, 2026 | Paul Andrew Moore | Exercise M | 20.0K | $0 |
| Jan 5, 2026 | Paul Andrew Moore | Exercise M | 17.2K | $0 |
| Jan 5, 2026 | Paul Andrew Moore | Sell S | 10.8K | $271.6K |
| Jan 5, 2026 | Paul Andrew Moore | Exercise M | 20.0K | $0 |
| Jan 5, 2026 | Paul Andrew Moore | Sell S | 9.3K | $233.1K |
| Jan 5, 2026 | Paul Andrew Moore | Exercise M | 17.2K | $0 |
| Jan 5, 2026 | Kenneth Galbraith KEY | Exercise M | 66.7K | $0 |
| Jan 5, 2026 | Kenneth Galbraith KEY | Exercise M | 47.7K | $0 |
| Jan 5, 2026 | Kenneth Galbraith KEY | Sell S | 31.7K | $795.2K |
| Jan 5, 2026 | Kenneth Galbraith KEY | Exercise M | 66.7K | $0 |
| Jan 5, 2026 | Kenneth Galbraith KEY | Sell S | 22.7K | $568.6K |
| Jan 5, 2026 | Kenneth Galbraith KEY | Exercise M | 47.7K | $0 |
About ZYME insider trading
This page tracks insider transactions for Zymeworks Inc. (ZYME) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.